Natrecor Safety Confirmed In ADHERE Heart Failure Registry, J&J Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson defends safety of nesiritide, says hospital registry shows Natrecor is associated with significantly lower mortality rate than milrinone or dobutamine, and a rate equivalent to that of nitroglycerin.
You may also be interested in...
J&J Natrecor "Dear Doctor" Letter Discusses Appropriate Use In Heart Failure
Scios uses "Dear Doctor" letter to alert physicians to independent panel's recommendations for appropriate and inappropriate uses of nesiritide. The letter recommends use of Natrecor only in a clinical setting where blood pressure can be closely monitored.
J&J Natrecor "Dear Doctor" Letter Discusses Appropriate Use In Heart Failure
Scios uses "Dear Doctor" letter to alert physicians to independent panel's recommendations for appropriate and inappropriate uses of nesiritide. The letter recommends use of Natrecor only in a clinical setting where blood pressure can be closely monitored.
Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says
The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.